Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for Vivos Therapeutics (VVOS) over the last 6 years, with Q3 2025 value amounting to -$83000.0.

  • Vivos Therapeutics' Capital Expenditures fell 14322.92% to -$83000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $975000.0, marking a year-over-year increase of 7165.49%. This contributed to the annual value of $568000.0 for FY2024, which is 2926.53% down from last year.
  • Per Vivos Therapeutics' latest filing, its Capital Expenditures stood at -$83000.0 for Q3 2025, which was down 14322.92% from $771000.0 recorded in Q2 2025.
  • Vivos Therapeutics' Capital Expenditures' 5-year high stood at $1.3 million during Q2 2021, with a 5-year trough of -$83000.0 in Q3 2025.
  • For the 5-year period, Vivos Therapeutics' Capital Expenditures averaged around $289526.3, with its median value being $192000.0 (2024).
  • Its Capital Expenditures has fluctuated over the past 5 years, first skyrocketed by 1670123.03% in 2021, then plummeted by 14322.92% in 2025.
  • Vivos Therapeutics' Capital Expenditures (Quarter) stood at $382000.0 in 2021, then crashed by 47.64% to $200000.0 in 2022, then decreased by 17.5% to $165000.0 in 2023, then changed by 0.0% to $165000.0 in 2024, then crashed by 150.3% to -$83000.0 in 2025.
  • Its Capital Expenditures was -$83000.0 in Q3 2025, compared to $771000.0 in Q2 2025 and $122000.0 in Q1 2025.